Effects of HuR downregulation on anaplastic thyroid cancer cells

Allegri,Lorenzo; Mio,Catia; Russo,Diego; Filetti,Sebastiano; Baldan,Federica

doi:10.3892/ol.2017.7289

Effects of HuR downregulation on anaplastic thyroid cancer cells

Authors:
- Lorenzo Allegri
- Catia Mio
- Diego Russo
- Sebastiano Filetti
- Federica Baldan
View Affiliations

Affiliations: Department of Medical and Biological Sciences, University of Udine, I‑33100 Udine, Italy, Department of Health Sciences, ‘Magna Graecia’ University of Catanzaro, I‑88100 Catanzaro, Italy, Department of Internal Medicine and Medical Specialties, ‘Sapienza’ University of Rome, I‑00161 Rome, Italy
Published online on: October 30, 2017 https://doi.org/10.3892/ol.2017.7289
Pages: 575-579

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anaplastic thyroid cancer (ATC) constitutes one of the most aggressive types of human solid cancer, and is characterized by the absence of thyroid differentiation features and a marked degree of invasiveness. We have previously demonstrated that the RNA‑binding protein Hu antigen R (HuR) is overexpressed in thyroid carcinoma; thus, the biological role of this RNA‑binding protein was investigated in the present study using the ATC cell lines SW1736 and 8505C. In both cell lines, HuR protein levels were higher compared with in the non‑tumorigenic thyroid cell line Nthy‑ori‑3.1. HuR silencing by RNA interference in both ATC cell lines decreased cell viability, increased apoptosis rates and reduced the capability to form colonies in soft agar. Thus, HuR plays an important role in the proliferation and aggressiveness of ATC cells. The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) was able to reduce the viability of ATC cells. The results demonstrated that SAHA was able to decrease HuR expression in SW1736 and 8505C cells. Furthermore, since it is known that the transcription factor nuclear factor (NF)‑κB modulates HuR expression, whether SAHA affects the nuclear (active) fraction of NF‑κB in ATC cells was investigated. The data suggested that SAHA decreases ATC cell viability by reducing the active form of NF‑κB, which, in turn, modulates HuR expression.

View Figures

View References

1	Schwanhäusser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W and Selbach M: Global quantification of mammalian gene expression control. Nature. 473:337–342. 2011. View Article : Google Scholar : PubMed/NCBI
2	Kechavarzi B and Janga SC: Dissecting the expression landscape of RNA-binding proteins in human cancers. Genome Biol. 15:R142014. View Article : Google Scholar : PubMed/NCBI
3	Wurth L and Gebauer F: RNA-binding proteins, multifaceted translational regulators in cancer. Biochim Biophys Acta. 1849:881–886. 2015. View Article : Google Scholar : PubMed/NCBI
4	Abdelmohsen K and Gorospe M: Posttranscriptional regulation of cancer traits by HuR. Wiley Interdiscip Rev RNA. 1:214–229. 2010. View Article : Google Scholar : PubMed/NCBI
5	Wurth L: Versatility of RNA-binding proteins in cancer. Comp Funct Genomics. 2012:1785252012. View Article : Google Scholar : PubMed/NCBI
6	Wang J, Guo Y, Chu H, Guan Y, Bi J and Wang B: Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis. Int J Mol Sci. 14:10015–10041. 2013. View Article : Google Scholar : PubMed/NCBI
7	Govindaraju S and Lee BS: Adaptive and maladaptive expression of the mRNA regulatory protein HuR. World J Biol Chem. 4:111–118. 2013. View Article : Google Scholar : PubMed/NCBI
8	Baldan F, Mio C, Allegri L, Conzatti K, Toffoletto B, Puppin C, Radovic S, Vascotto C, Russo D, Di Loreto C and Damante G: Identification of tumorigenesis-related mRNAs associated with RNA-binding protein HuR in thyroid cancer cells. Oncotarget. 7:63388–63407. 2016. View Article : Google Scholar : PubMed/NCBI
9	Pellegriti G, Frasca F, Regalbuto C, Squatrito S and Vigneri R: Worldwide increasing incidence of thyroid cancer: Update on epidemiology and risk factors. J Cancer Epidemiol. 2013:9652122013. View Article : Google Scholar : PubMed/NCBI
10	Lebastchi AH and Callender GG: Thyroid cancer. Curr Probl Cancer. 38:48–74. 2014. View Article : Google Scholar : PubMed/NCBI
11	O'Neill JP and Shaha AR: Anaplastic thyroid cancer. Oral Oncol. 49:702–706. 2013. View Article : Google Scholar : PubMed/NCBI
12	Chaitanya GV, Alexander JS and Babu PP: PARP-1 cleavage fragments: Signatures of cell-death proteases in neurodegeneration. Cell Commun Signal. 8:312010. View Article : Google Scholar : PubMed/NCBI
13	Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X and Marks PA: Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA. 102:pp. 673–678. 2005; View Article : Google Scholar : PubMed/NCBI
14	Baldan F, Mio C, Allegri L, Puppin C, Russo D, Filetti S and Damante G: Synergy between HDAC and PARP inhibitors on proliferation of a human anaplastic thyroid cancer-derived cell line. Int J Endocrinol. 2015:9783712015. View Article : Google Scholar : PubMed/NCBI
15	Zhang J, Ouyang W, Li J, Zhang D, Yu Y, Wang Y, Li X and Huang C: Suberoylanilide hydroxamic acid (SAHA) inhibits EGF-induced cell transformation via reduction of cyclin D1 mRNA stability. Toxicol Appl Pharmacol. 263:218–224. 2012. View Article : Google Scholar : PubMed/NCBI
16	Kang M, Ryu B, Lee M, Han J, Lee JH, Ha TK, Byun DS, Chae KS, Lee BH, Chun HS, et al: NF-kappaB activates transcription of the RNA-binding factor HuR, via PI3K-AKT signaling, to promote gastric tumorigenesis. Gastroenterology. 135:2030–2042.e1-3. 2008. View Article : Google Scholar : PubMed/NCBI
17	Gilmore TD: Introduction to NF-kappaB: Players, pathways, perspectives. Oncogene. 25:6680–6684. 2006. View Article : Google Scholar : PubMed/NCBI
18	Perkins ND: Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol. 8:49–62. 2007. View Article : Google Scholar : PubMed/NCBI
19	Srikantan S and Gorospe M: HuR function in disease. Front Biosci (Landmark Ed). 17:189–205. 2012. View Article : Google Scholar : PubMed/NCBI
20	Blaxall BC, Dwyer-Nield LD, Bauer AK, Bohlmeyer TJ, Malkinson AM and Port JD: Differential expression and localization of the mRNA binding proteins, AU-rich element mRNA binding protein (AUF1) and Hu antigen R (HuR), in neoplastic lung tissue. Mol Carcinog. 28:76–83. 2000. View Article : Google Scholar : PubMed/NCBI
21	Mann BS, Johnson JR, Cohen MH, Justice R and Pazdur R: FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 12:1247–1252. 2007. View Article : Google Scholar : PubMed/NCBI